Sanofi and Regeneron say they have placed their rheumatoid arthritis medication, Kevzara, into immediate clinical trials in the fight against COVID-19. The drugmakers will initially focus on Kevzara’s effect on fever and patients’ need for supplemental oxygen. For the treatment of rheumatoid arthritis, Kevzara currently holds preferred status for just 1% of covered lives, growing to 8% with prior authorization and/or step therapy.

SOURCE: MMIT Analytics, as of 3/18/20